Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-12-16
2000-04-04
Mullis, Jeffrey
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546296, A01N 4340
Patent
active
060462191
ABSTRACT:
The present invention relates to a method of treating conditions mediated by collagen formation together with cell proliferation by administering to a patient or living system an effective amount of a compound of Formulae (I) or (II) and derivatives thereof: ##STR1## R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.
REFERENCES:
patent: 4248892 (1981-02-01), Kanamara et al.
patent: 4260599 (1981-04-01), Okazaki
patent: 4514520 (1985-04-01), Imada et al.
patent: 4569943 (1986-02-01), Okazaki et al.
patent: 4604407 (1986-08-01), Haslanger et al.
patent: 4797471 (1989-01-01), Teetz et al.
patent: 4897391 (1990-01-01), Friary
patent: 4904675 (1990-02-01), Winter-Mihaly
patent: 4908371 (1990-03-01), Moeker et al.
patent: 4912111 (1990-03-01), Sank
patent: 4937266 (1990-06-01), Tomikawa et al.
patent: 4997854 (1991-03-01), Kagan et al.
patent: 5037839 (1991-08-01), Bickel et al.
patent: 5132119 (1992-07-01), Lee
patent: 5158979 (1992-10-01), Clarkson, Jr. et al.
patent: 5182297 (1993-01-01), Palfreyman
patent: 5204338 (1993-04-01), Baader et al.
patent: 5252608 (1993-10-01), Palfreyman
patent: 5252735 (1993-10-01), Morris
patent: 5260323 (1993-11-01), Baader et al.
patent: 5518729 (1996-05-01), Margolin
patent: 5620995 (1997-04-01), Weidmann et al.
patent: 5658933 (1997-08-01), Weidmann et al.
HCAPLUS 1995:349979, Document 122:178020 (Abstract: McCaffrey, et al., "Specific Inhibition of elF-5A and Collagen Hydroxylation by a Single Agent. Antiproliferative and Fibrosuppressive Effects on Smooth Muscle Cells From Human Coronary Arteries," J. Clin. Invest. 95(2):446-55 (1995)).
Librojo et al., "Metabolism of Mimosine and Other Compounds from Leucaena Leucocephala by the Chicken," Nutrition Reports International, 9(3):217-22 (1974).
Hanauske-Abel et al., "Inhibition of the G1-S Transition of the Cell Cycle by Inhibitors of Deoxyhypusine Hydroxylation," Biochimica et Biophysica Acta, pp. 1-12 (1994).
Hanauske-Abel et al., "The Deoxyhypusyl Hydroxylase Inhibitor Mimosine Induces Monocytic Differentiation of HL-60 Cells," Presentation to the Congress of the International Society for Analytical Cytology (Mar. 21-26, 1993).
Tang et al., "The Inhibitory Effect of Mimosine on Collagen Synthesis," Toxicon, 13:339-42 (1975).
Hanauske-Abel, H.M., "Proly 4-Hydroxylase, a Target Enzyme for Drug Development," Journal of Hepatology, 13(suppl. 3):S8-S16 (1991).
Fouser, et al., "Transcriptional Activity of the .alpha.1(I)-Collagen Promoter is Correlated with the Formation of Capillary-Like Structures by Endothelial Cells in Vitro," The Journal of Biological Chemistry, 266(27):18345-51 (1991).
Iruela-Arispe, et al., "Modulation of Extracellular Matrix Proteins by Endothelial Cells Undergoing Angiogenesis In Vitro," Arterioscler. Thromb., 11:805-15 (1991).
Sage, et al., "Regulation of Angiogenesis by Extracellular Matrix: The Growth and the Glue," J. Hypertens,, 12:S145-S152 (1994).
Vernon, et al., "Organized Type I Collagen Influences Endothelial Patterns During "Spontaneous Angiogenesis in Vitro": Planar Cultures as Models of Vascular Development," In Vitro Cell. Dev. Biol., 31:120-31 (1995).
Jarvelainen, et al., "Expression of Decorin by Sprouting Bovine Aortic Endothelial Cells Exhibitng Angiogenesis in Vitro," Experimental Cell Research, 203:395-401 (1992).
Kanzawa, et al., "Improved In Vitro Angiogenesis Model by Collagen Density reduction and the Use of Type III Collagen," Ann. Plat. Surg., 30:244-51 (1993).
Maragoudakis, et al., "Validation of Collagenous Protein Synthesis as an Index for Angiogenesis with the Use of Morphological Methods," Microvascular Research, 50:215-22 (1995).
Iruela-Arispe, et al., "Differential Expression of Extracellular Proteins is Correlated with Angiogenesis In Vitro," Lab. Invest., 64(2):174-86 (1991).
Nicosia, et al., "Regulation of Angiogenesis In Vitro by Collagen Metabolisml" In Vitro Cell. Dev. Biol., 27A:961-66 (1991).
Ingber, et al., "Inhibition of Angiogenesis Through Modulation of Collagen Metabolism," Lab. Invest., 59(1):44-51 (1988).
Haralabopoulos, et al., "Inhibitors of Basement Membrane Collagen Synthesis Prevent Endothelial Cell Alignment in Matrigel In Vitro and Angiogenesis In Vivo," Lab. Invest., 71(4):575-82 (1994).
Maragoudakis, et al., "Basement Membrane Biosynthesis as a Target for Developing Inhibitors of Angiogenesis with Anti-Tumor Properties," Kidney International, 43:147-50 (1993).
Grady et al., WPRDS AN-96-354238, 1996.
Grady Robert W.
Hanauske-Abel Hartmut M.
McCaffrey Timothy A.
Cornell Research Foundation Inc.
Mullis Jeffrey
Peabody LLP Nixon
LandOfFree
Method for the treatment of conditions mediated by collagen form does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of conditions mediated by collagen form, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of conditions mediated by collagen form will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365673